AbbVie Inc.

🇺🇸New York Stock Exchange

Articles

46
Show Summary
Show Bulletpoints
Detailed View
Bullish +75

Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

📈 Piper Sandler raised AbbVie's price target to $298 with an Overweight rating.

💊 Strong investor interest stems from the extensive IBD pipeline and 18 new research abstracts.

🔬 ASPIRE-CD data confirms lasting symptom improvements for Crohn's patients on risankizumab.

📈 Piper Sandler raised its price target on AbbVie (ABBV) from $294 to $298 on May 14.

⚖️ The firm retained an Overweight rating on AbbVie shares following the update.

💊 Investor interest is driven by AbbVie's extensive pipeline for inflammatory bowel disease (IBD).

📅 AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting in Chicago.

🔬 The research focused on real-world evidence and long-term results for SKYRIZI and RINVOQ therapies.

🧪 ASPIRE-CD study data showed 52-week follow-up results for risankizumab-treated Crohn's patients.

📉 Treated individuals demonstrated lasting improvements in liquid stools, bowel urgency, and abdominal pain.

🤝 Piper Sandler views management's pursuit of novel combination methods as a positive development.

🔍 The firm highlights R&D opportunities beneath the radar of the general investment market.

💼 AbbVie is described as a research-based biopharmaceutical company with global operations.

⚠️ The article includes unrelated promotional content regarding AI stocks and other investment picks.

📰 Additional links promote lists of undervalued dividend stocks and hedge fund strategies.

Bullish Signals
  • Piper Sandler raised AbbVie (NYSE: ABBV) price target to $298.
  • AbbVie submitted 18 IBD abstracts at 2026 Digestive Disease Week in Chicago.
  • ASPIRE-CD study showed risankizumab improved Crohn's disease symptoms long-term.
  • Novel IBD combination methods viewed as positive competitive development.
  • AbbVie has undervalued R&D shots-on-goal beneath general investment market radar.
Risk Factors
  • Promotional bias from unrelated stock mentions like 'BAC' and AI.
  • Lead generation focus undermines deep AbbVie risk analysis.
  • Date discrepancies imply hypothetical data misleading current performance.
  • Omits patent cliff risks for SKYRIZI and RINVOQ.
Bullish Signals
  • Piper Sandler raised its price target for AbbVie (NYSE: ABBV) to $298 from $294 on May 14, retaining an Overweight rating.
  • AbbVie submitted 18 abstracts on inflammatory bowel illnesses at the 2026 Digestive Disease Week Annual Meeting held in Chicago from May 2 to 5.
  • The ASPIRE-CD study demonstrated that risankizumab-treated individuals with moderately to highly active Crohn's disease had long-lasting improvements in liquid stools, bowel urgency, and abdominal pain.
  • Management's pursuit of novel combination methods in IBD is viewed as a positive development given the competitiveness of the IBD medication development landscape.
  • AbbVie possesses a variety of R&D shots-on-goal that remain beneath the radar of the general investment market.
Risk Factors
  • The article contains promotional content for other stocks, specifically mentioning 'BAC' and AI stocks with '10,000% upside potential', which may indicate a lack of focus or potential bias in the analysis of AbbVie.
  • The text includes generic marketing copy about 'Top 12 Undervalued Dividend Stocks' and '33 Stocks That Should Double in 3 Years', suggesting the primary purpose is lead generation rather than providing deep, critical financial analysis of AbbVie's specific risks.
  • There is a significant discrepancy in dates within the article, mentioning a meeting held in 'May 2 to 5' and returns calculated through 'February 18th, 2026', which implies the data may be hypothetical or the article is using future-dated scenarios that could mislead investors about current performance.
  • The article fails to mention any specific financial risks associated with AbbVie's reliance on its IBD pipeline, such as potential patent cliffs for SKYRIZI and RINVOQ or regulatory hurdles for new combination therapies.
Slightly Bullish +25

AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor - AD HOC NEWS

📉 Q1 2024 revenues hit $12.3B amid Humira declines offset by Skyrizi and Rinvoq growth.

💊 New immunology therapies drive transition as biosimilar competition erodes flagship drug sales.

🧬 Diversified portfolio spans oncology, neuroscience, and aesthetics to reduce single-product dependence.

📉 AbbVie reported Q1 2024 worldwide net revenues of approximately $12.3 billion, reflecting continued year-over-year declines in its flagship drug Humira.

💊 The company is executing a strategic transition where newer immunology therapies Skyrizi and Rinvoq are offsetting the erosion from declining Humira sales.

📈 Skyrizi delivered strong double-digit sales growth in Q1 2024, driven by market share gains and new indications for plaque psoriasis and Crohn's disease.

💉 Rinvoq also showed significant sales increases in the first quarter of 2024, supported by wider adoption in rheumatology and dermatology markets.

🧬 AbbVie maintains a diversified business model across immunology, oncology, neuroscience, eye care, and aesthetics to reduce dependence on any single product.

💰 The oncology portfolio includes Imbruvica and Venclexta, though Imbruvica faces competitive pressure from newer BTK inhibitors and changing treatment guidelines.

🧠 Neuroscience treatments target psychiatric and neurological conditions, representing long-term opportunities as populations age and diagnosis rates improve.

💅 The aesthetics franchise, anchored by Botox Cosmetic and Juvéderm, emerged from the 2020 acquisition of Allergan to broaden revenue streams.

🇺🇸 AbbVie's revenue model is heavily influenced by the US healthcare system, where pricing levels and reimbursement frameworks support higher margins than international markets.

⚖️ Investors closely monitor US policy debates regarding drug costs and Medicare negotiations, which could impact pricing on key products over time.

🔬 The company invests billions annually in research and development with a focus on immunology, oncology, and neuroscience programs to replenish revenues lost to patent expirations.

🤝 AbbVie balances internal discovery efforts with external collaborations and licensing deals to access innovative technologies and niche expertise.

📊 Humira sales faced significant year-over-year declines in Q1 2024, particularly in the United States, as payers promoted lower-priced biosimilar competitors.

🏛️ The company is listed on the New York Stock Exchange under the ticker ABBV and is included in major equity indices held by many US savers.

💵 AbbVie has historically returned a substantial portion of cash to shareholders through regular dividends, attracting income-focused investors.

⚠️ Management reiterated its focus on execution in the US market and provided updated guidance for full-year adjusted earnings per share.

🌍 Competitors in the immunology space include Johnson & Johnson, Novartis, and Eli Lilly, intensifying the race for targeted and efficacious treatments.

📉 The integration of Allergan brought cost synergies and operational efficiencies but also increased the company's debt load and ongoing investment requirements.

🧪 Clinical trial milestones and regulatory submissions from authorities like the US FDA can rapidly alter expectations for AbbVie's long-term revenue trajectory.

📉 Biosimilar competition began eroding Humira's market share in Europe several years ago and reached the US market in 2023, putting pressure on revenue and margins.

🔮 Management views the transition to a diversified portfolio as central to long-term value creation despite the challenges of patent cliffs and regulatory decisions.

Bullish Signals
  • AbbVie reported $12.3B Q1 2024 net revenues.
  • Skyrizi shows strong double-digit sales growth in Q1 2024.
  • Rinvoq sales increased strongly versus prior year in Q1 2024.
  • Aesthetics franchise anchored by Botox Cosmetic offers attractive margins.
  • 2020 Allergan acquisition diversified revenue base and created cross-selling.
Risk Factors
  • Humira sales decline due to biosimilar competition erosion.
  • Oncology assets face headwinds from new BTK inhibitors.
  • Aesthetics demand sensitive to US macroeconomic conditions.
  • US healthcare policy changes impact pricing power.
  • Company navigates Humira patent cliffs with new therapies.
Bullish Signals
  • AbbVie reported worldwide net revenues of around 12.3 billion USD for the first quarter of 2024, demonstrating continued financial scale despite transition challenges.
  • Newer immunology therapies Skyrizi and Rinvoq are delivering significant growth to offset declining Humira sales, with Skyrizi showing strong double-digit sales growth versus the prior-year period in Q1 2024.
  • Rinvoq sales increased strongly compared with the same period a year earlier in Q1 2024, supported by wider adoption in rheumatology and dermatology markets.
  • The company's aesthetics franchise, anchored by Botox Cosmetic and Juvéderm, offers attractive margins and strong brand recognition that complement traditional prescription drug lines.
  • AbbVie has diversified its revenue base through the 2020 acquisition of Allergan, reducing dependence on any single product and creating cross-selling opportunities across neurology, ophthalmology, and aesthetics.
  • Management reiterated a focus on immunology, oncology, and neuroscience as core long-term pillars, signaling confidence in the company's strategic direction and future growth drivers.
  • AbbVie continues to invest billions of dollars annually in research and development with an emphasis on immunology, oncology, and neuroscience programs to replenish revenues lost to patent expirations.
  • The company has a history of returning a substantial portion of cash to shareholders through regular dividends, making it attractive for income-focused investors.
  • AbbVie is listed on the New York Stock Exchange under ticker ABBV and is included in major equity indices, providing accessibility for US retail investors and inclusion in diversified portfolios.
Risk Factors
  • AbbVie reported first-quarter 2024 worldwide net revenues of approximately $12.3 billion, reflecting continued year-over-year declines in its blockbuster immunology drug Humira due to significant erosion from biosimilar competition.
  • Humira sales declined particularly in the United States where payers and pharmacy benefit managers are increasingly promoting lower-priced competitors following the 2023 market entry of biosimilars.
  • Oncology assets like Imbruvica face competitive headwinds from newer BTK inhibitors and changing treatment guidelines, which has weighed on oncology growth despite contributions from Venclexta.
  • The aesthetics franchise led by Botox Cosmetic and Juvéderm remains sensitive to macroeconomic conditions, as demand for aesthetic procedures is influenced by consumer confidence and discretionary spending tied to the health of the US economy.
  • AbbVie's revenue model is heavily influenced by US healthcare policy changes, including Medicare price negotiations and inflation-related rebates, which could impact pricing power for key products.
  • The company faces a complex transition as it navigates patent cliffs for Humira while attempting to offset declining revenues with growth from newer therapies Skyrizi and Rinvoq.
  • AbbVie's broad geographic footprint in aesthetics combined with strong brand recognition allows it to maintain presence, yet competition intensifies in this segment.
Slightly Bullish +25

AbbVie in Canada Appoints Tanu Misra as Vice President and General ...

📅 Tanu Misra appointed VP and GM leading AbbVie Canada operations May 11, 2026.

👩‍💼 She brings over 38 years of experience from Abbott Laboratories and AbbVie.

💊 Her team will develop medicines for one million Canadian patients annually.

📅 On May 11, 2026, AbbVie announced the appointment of Tanu Misra as Vice President and General Manager to lead its operations in Canada.

👩‍💼 Tanu Misra joins with over 38 years of industry experience, having been with Abbott Laboratories for more than ten years prior to her tenure at AbbVie.

🌎 She officially started her new role leading a workforce of more than 1,000 employees across Canada.

💊 Under her leadership, the company aims to discover and develop medicines impacting one million patients annually in Canada.

🧬 Key therapeutic areas include immunology, neuroscience, oncology, and products within the Allergan Aesthetics portfolio.

📈 Misra previously held the role of Vice President for Dermatology Psoriatic and U.S. Immunology, where she drove sustained commercial growth.

🤝 Her appointment aligns with AbbVie's purpose to translate innovation into meaningful health outcomes and partner with the healthcare community.

❤️ She is actively committed to community service, specifically serving on the Board of Bernie's Book Bank supported by the AbbVie Foundation.

📖 Through her involvement with Bernie's Book Bank, she champions children's literacy to help empower future readers and leaders in Canada.

🌐 For additional updates on this appointment, stakeholders are directed to visit www.abbvie.ca or follow the company's social media channels.

Bullish Signals
  • Experienced leadership with Tanu Misra's 12+ years tenure drives sustained growth.
  • Commercial excellence expertise ensures strong AbbVie Canada portfolio leadership.
  • Robust Canadian team treats ~1 million patients annually with innovation.
  • Strategic focus aligns vision to deliver meaningful patient health outcomes.
  • Expansion covers immunology, neuroscience, oncology, and Allergan Aesthetics.
Risk Factors
  • AbbVie provides no specific revenue or sales forecast guidance.
  • No market share updates included in recent announcement.
  • Tanu Misra lacks immediate turnaround transformation experience.
Bullish Signals
  • AbbVie is well-positioned to leverage experienced leadership with Tanu Misra's 12+ years of tenure at the company, including recent success in driving sustained growth within U.S. Immunology and Dermatology Psoriatic segments.
  • Tanu Misra brings deep commercial excellence expertise from her more than ten years spent at Abbott Laboratories Inc., ensuring continuity and strong portfolio leadership for AbbVie Canada.
  • With over 1,000 employees across Canada, AbbVie has a robust team ready to deliver innovative medicines that currently treat approximately one million patients annually in the Canadian healthcare system.
  • The company's strategic focus on advancing science and healthcare policies aligns with Tanu Misra's vision to translate innovation into meaningful health outcomes for patients across Canada.
  • AbbVie continues to expand its remarkable impact through key therapeutic areas including immunology, neuroscience, oncology, and the Allergan Aesthetics portfolio.
Risk Factors
  • The announcement of Tanu Misra's appointment as Vice President and General Manager provides no specific revenue guidance, market share updates, or sales forecasts for AbbVie in Canada.
  • Tanu Misra joined AbbVie in 2012 but previously spent more than ten years at Abbott Laboratories, indicating she is a long-tenured executive rather than an external hire to immediately transform the Canadian business.
Bullish +75

AbbVie Stock Deserves A Higher Multiple (NYSE:ABBV) - Seeking Alpha

📈 Buy AbbVie stock as fundamentals strengthen near multi-year valuation lows.

📊 Revenue jumped 12.4% in Q1 despite immunology portfolio challenges.

🏭 Company invested $1.4B in North Carolina to support innovation and mitigate risk.

📈 AbbVie stock is recommended as a buy due to strengthening fundamentals and valuation near multiyear lows.

📊 Q1 net revenues increased 12.4% year-over-year, showing robust business activity despite immunology portfolio challenges.

📅 Management raised full-year 2026 EPS guidance, projecting underlying annual growth of 14% after adjusting for IPR&D and milestone impacts.

🏭 The company invested $1.4B in a North Carolina campus to support long-term innovation and mitigate political risk.

🧪 Earlier guidance cuts were dismissed as noise, attributed to normal IPR&D and milestone expenses rather than operational weakness.

💡 The article argues that the current underperformance creates an opportunity for the stock to trade at a higher multiple.

⚠️ The immunology portfolio is described as experiencing some shakiness despite overall revenue growth.

👤 The author is a full-time tech-sector investor with a Bachelor of Commerce Degree and a member of Beta Gamma Sigma.

🛡️ Both the author and Seeking Alpha include standard disclosures stating no conflict of interest or licensed investment advice.

📝 The analysis concludes that AbbVie remains an attractive investment opportunity for value-oriented investors.

Bullish Signals
  • A buy as fundamentals strengthen near multiyear lows.
  • Q1 net revenues grew 12.4% year-over-year.
  • Raised full-year 2026 EPS guidance with 14% annual growth.
  • $1.4B North Carolina campus reinforces long-term innovation.
  • Underperformance offers opportunity given improved outlook.
Risk Factors
  • Immunology portfolio shakiness indicates core business instability.
  • 2026 EPS guidance requires IPR&D and milestone adjustments.
Bullish Signals
  • AbbVie Inc. (ABBV) remains a buy as fundamentals strengthen while valuation sits near multiyear lows.
  • Q1 net revenues grew 12.4% year-over-year, indicating robust overall business activity.
  • Management raised full-year 2026 EPS guidance, signaling confidence with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.
  • Strategic investments, including a $1.4B North Carolina campus, reinforce AbbVie's long-term innovation and mitigate political risk.
  • Recent stock underperformance presents an opportunity given the improved fundamental outlook.
Risk Factors
  • The article explicitly acknowledges 'Immunology portfolio shakiness', indicating potential instability or weakness in a core business segment despite overall revenue growth.
  • Full-year 2026 EPS guidance is based on projections that require adjustment for Intellectual Property and Research & Development (IPR&D) and milestone impacts, suggesting non-recurring expenses could affect reported earnings in the future.
Bullish +65

AbbVie Stock: Is Wall Street Bullish or Bearish?

📉 AbbVie recently underperformed broader indices but beat the Pharmaceutical ETF.

💰 FY2026 Q1 revenue hit $15B, beating estimates and raising EPS guidance.

📈 Immunology drives growth while 32 analysts maintain a Moderate Buy rating.

🏢 AbbVie Inc., headquartered in North Chicago, is a major global pharmaceutical leader with a $356.4 billion market capitalization.

📉 The stock has trailed the broader S&P 500 Index over the past year, rising only 8.6% compared to the index's 30.6% rally.

📊 In fiscal 2026 year-to-date, AbbVie shares dropped 11.8%, underperforming the S&P 500 which gained 8.1%.

💼 Despite trailing broader indices, AbbVie has outperformed the Vaneck Pharmaceutical ETF (PPH), which gained 16.5% in the same period.

📅 On April 29, AbbVie reported FY2026 Q1 earnings with total net revenue of $15 billion, a 12.4% year-over-year increase.

🤑 The company beat Wall Street expectations for revenue of roughly $14.7 billion and delivered adjusted EPS of $2.65.

💡 Management maintained an optimistic tone after the quarter and raised its full-year 2026 adjusted EPS guidance to $14.08–$14.28.

🔬 Immunology continues to serve as the primary growth engine for AbbVie's business operations.

📈 Analysts now expect AbbVie's current fiscal year EPS to improve by 43.2% year over year to reach $14.32.

🏆 The company has a solid earnings surprise history, exceeding consensus estimates in each of the last four consecutive quarters.

📊 Wall Street maintains a "Moderate Buy" consensus rating based on 32 analysts covering the stock.

👍 Among analysts, 20 recommend "Strong Buy," two suggest "Moderate Buy," and ten advise a "Hold."

⬆️ The bullish sentiment has increased slightly compared to a month ago, with 17 analysts now suggesting "Strong Buy."

💼 Evercore ISI analyst Gavin Clark-Gartner reiterated an "Outperform" rating and raised the price target to $236.

🎯 The average analyst price target of $251.03 implies a potential 24.5% premium to current stock prices.

🚀 The Street-high target of $294 represents significant upside potential of 45.9% from current levels.

Bullish Signals
  • Revenue hit $15 billion, up 12.4% year-over-year.
  • Adjusted EPS reached $2.65, beating estimates at $2.59.
  • Full-year 2026 EPS guidance raised to $14.08-$14.28.
  • Analysts expect current fiscal year EPS growth of 43.2%.
  • Stock holds 'Moderate Buy' rating with 20 out of 32 strong buys.
  • Outperform rating reiterated with price target raised to $236.
  • Highest price target $294 offers 45.9% upside potential.
Risk Factors
  • Shares trailed the S&P 500 significantly over the last year and recent periods.
  • Underperformance persists despite beating Q1 FY2026 earnings estimates.
  • Weak market enthusiasm follows strong revenue and adjusted EPS beats.
  • Expected EPS growth may fail to offset significant index underperformance.
  • Majority of analysts rate the stock as 'Hold'.
Bullish Signals
  • AbbVie reported FY2026 Q1 earnings with total net revenue of $15 billion, representing a 12.4% year-over-year increase that beat Wall Street expectations.
  • The company posted adjusted EPS of $2.65 per share, which was a 7.7% increase from the previous year and exceeded analyst estimates of $2.59.
  • Management raised its full-year 2026 adjusted EPS guidance to a range of $14.08 to $14.28, up from the prior forecast of $13.96 to $14.16.
  • Analysts expect ABBV's EPS to improve 43.2% year-over-year for the current fiscal year, ending in December.
  • AbbVie has a history of solid earnings surprises, exceeding the consensus estimate in each of the last four consecutive quarters.
  • The stock currently holds a consensus 'Moderate Buy' rating with 20 out of 32 analysts recommending a 'Strong Buy'.
  • Analyst Gavin Clark-Gartner reiterated an 'Outperform' rating and raised his price target to $236 from $232.
  • The Street-high price target of $294 represents significant upside potential of 45.9% from current levels.
Risk Factors
  • Shares of AbbVie have trailed the broader S&P 500 Index significantly, rising only 8.6% over the last year compared to the market's 30.6% rally.
  • In 2026, ABBV dropped 11.8%, underperforming the SPX's 8.1% return on a year-to-date basis, highlighting recent weakness relative to the broader market.
  • Despite beating earnings estimates in FY2026 Q1 with revenue of $15 billion and adjusted EPS of $2.65, the stock price rose only 3.1% following the report, suggesting muted market enthusiasm.
  • The current fiscal year's expected EPS improvement of 43.2% year over year to $14.32 may not fully offset the significant underperformance against the S&P 500 index over the trailing twelve months.
  • A large portion of analysts advise a 'Hold' rating on the stock, with ten out of 32 covering analysts suggesting caution despite several 'Strong Buy' recommendations.
Bullish +75

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

📈 AbbVie achieved record $61.2B revenue and $10.54 EPS, beating guidance despite Humira erosion.

🤝 A voluntary deal secures innovation protection via tariffs mitigation and low Medicaid pricing.

💼 The company invested over $5B in business development with ample cash flow support.

💰 Dividends rose 5.5% to $1.73/share while recent drug approvals expanded the pipeline.

📈 AbbVie reported record 2025 net revenues of $61.2 billion, surpassing initial expectations by over $2 billion.

💰 Adjusted earnings per share reached $10.54, exceeding the company's initial guidance midpoint.

📊 Total sales grew 8.6%, reaching an all-time high despite nearly $16 billion in U.S. Humira erosion since losing exclusivity.

🏛️ Shareholders approved the election of Class II directors and ratified Ernst & Young as the external auditor.

⚖️ The advisory vote on executive compensation passed, but proposals to eliminate supermajority voting and for an independent board chair were rejected.

🔬 AbbVie fully funded approximately 90 clinical programs through substantially increased adjusted R&D investment.

💼 CEO Rob Michael stated that business development efforts targeted earlier-stage assets with a focus on growth extending into the 2030s.

💸 The company invested more than $5 billion in business development last year across immunology, neuroscience, oncology, and obesity.

🤝 AbbVie announced a three-year voluntary agreement with the U.S. government to advance access and affordability while protecting innovation.

⚖️ Key terms of the government deal include low Medicaid prices, expanded cash-pay options for specific drugs, and $100 billion in U.S. R&D and capital investments over the next decade.

🏭 The company committed $2.2 billion in manufacturing investments, including new facilities in North Chicago, Tempe, Worcester, and an expansion in Durham, North Carolina.

🛡️ CEO Rob Michael highlighted that the government agreement provides protection from pharmaceutical tariffs and future pricing mandates.

💹 CFO Scott Reents confirmed AbbVie has ample free cash flow to support dividends, internal R&D, business development, and maintaining an investment-grade credit rating.

💰 The quarterly dividend was increased by 5.5% in 2026 to $1.73 per share, with the February payable dividend being the first at this new rate.

📈 Historically, AbbVie has increased its quarterly dividend by more than 330% since inception, though future growth is not expected to match earnings growth rates.

✅ Recent pipeline approvals include Rinvoq for giant cell arteritis, Emrelis for non-squamous non-small cell lung cancer, and Epkinly for second-line follicular lymphoma.

📝 Regulatory submissions are underway for Rinvoq in alopecia areata and subcutaneous induction for Skyrizi in Crohn's disease.

🔬 Interim data from a study combining Skyrizi with the alpha-4 beta-7 program was presented, showing promising results for treating Crohn’s.

Bullish Signals
  • Record $61.2B revenue in 2025 beat expectations.
  • Sales grew 8.6% to an all-time high.
  • Adjusted EPS of $10.54 exceeded guidance midpoint.
  • Investment funds ~90 clinical programs for growth.
  • $5B business development focuses on 2030s expansion.
  • Ample capacity to acquire in immunology and oncology.
  • Quarterly dividend rose 5.5% to $1.73/share.
  • Secured tariff protection with $100B investment commitment.
  • Recent approvals include Rinvoq, Emrelis, and Epkinly.
Risk Factors
  • Annual meeting lacked discussion of potential downsides or risks.
  • $16 billion U.S. Humira revenue erosion pressures growth.
  • Two shareholder governance proposals failed at the annual meeting.
  • 2026 dividend growth will diverge from earnings growth rates.
  • $100 billion decade investment commitment drains near-term cash flow.
  • Earlier-stage pipeline focus introduces timing and success uncertainty.
Bullish Signals
  • AbbVie reported record total net revenues of $61.2 billion in 2025, exceeding initial expectations by more than $2 billion.
  • Sales growth of 8.6% drove the company to an all-time high for revenue, surpassing its previous peak by over $3 billion despite significant Humira erosion.
  • The company delivered adjusted earnings per share of $10.54, which beat the guidance midpoint excluding in-process research and development expenses.
  • Adjusted R&D investment was substantially increased to fully fund approximately 90 clinical programs currently in development.
  • AbbVie invested more than $5 billion in business development last year, focusing on earlier-stage assets to drive growth through the 2030s.
  • Management highlighted an ample financial capacity to acquire external innovation across immunology, neuroscience, oncology, and obesity sectors.
  • The company increased its quarterly dividend by 5.5% in 2026 to $1.73 per share, maintaining a strong track record with over 330% total dividend growth since inception.
  • AbbVie secured key elements of a three-year agreement with the U.S. government that offers tariff protection and commitment to $100 billion in R&D and capital investments over the next decade.
  • Recent pipeline approvals include Rinvoq for giant cell arteritis, Emrelis for non-squamous non-small cell lung cancer, and Epkinly for second-line follicular lymphoma.
Risk Factors
  • AbbVie's annual meeting was characterized as 'overwhelmingly positive,' lacking any discussion of potential downsides or risks that might counterbalance the record sales.
  • The company faced significant erosion of $16 billion from its U.S. Humira revenue due to loss of exclusivity, a key metric that continued to pressure growth despite overall revenue increases.
  • Two shareholder proposals regarding corporate governance failed: the management proposal to eliminate supermajority voting lacked the required vote, and an independent board chair proposal was rejected by more than 87% of the votes.
  • AbbVie's chairman indicated that quarterly dividend growth in 2026 will no longer match earnings growth rates, signaling a divergence in financial expansion metrics.
  • The company is committing $100 billion to U.S. research and development and capital investments over the next decade as part of a government agreement, which represents a massive near-term cash drain on balance sheets.
  • While AbbVie claims 'ample financial capacity,' its focus on earlier-stage assets for growth into the 2030s introduces uncertainty regarding the timing and commercial success of future pipeline approvals.
Bullish +75

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results | AbbVie

📈 Record 2025 sales achieved post-Humira exclusivity loss.

💰 2026 adjusted EPS guidance set between $14.37 and $14.57.

🚀 Growth driven by innovation, pipeline expansion, and diversified therapies.

AbbVie has reported its full-year and fourth-quarter 2025 financial results, highlighting record net sales achieved in the second year following the U.S. loss of exclusivity for Humira.

CEO Robert A. Michael described 2025 as an outstanding year that underscores the strength of the company's diversified growth platform despite the Humira expiration.

The company announced adjusted diluted EPS guidance for full-year 2026, projecting a range between $14.37 and $14.57 per share.

This forward guidance explicitly excludes any potential impact from acquired IPR&D and milestone payments incurred during 2026 due to forecasting uncertainty.

Management expects robust growth in 2026 driven by strong fundamentals, innovation investments, and a broadened treatment pipeline for patients.

The full-year results presentation includes both reported GAAP figures and non-GAAP measures to assist investors in evaluating operational performance.

Detailed financial tables for the quarter ended December 31, 2025, provide breakdowns of net revenues, costs of products sold, and selling general and administrative expenses.

Consolidated statements of earnings for the twelve months ended December 31, 2025, detail operating costs including research and development and acquired IPR&D.

Operational comparisons in the financial reports are presented at constant currency rates to reflect prior year's foreign exchange rates for clarity.

Specific revenue notes clarify that figures for Imbruvica international revenues and Epkinly U.S. revenues include profit sharing arrangements.

AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss the fourth-quarter performance and financial results.

The company includes standard forward-looking statement disclosures regarding risks such as intellectual property challenges, competition, litigation, and global macroeconomic factors.

Additional risk uncertainties also cover potential impacts from trade disputes, tariffs, international conflict, and changes in applicable laws and regulations.

An archived edition of the investor call will be available on AbbVie's Investor Relations website after 11:00 a.m. Central Time.

The company continues to focus on therapeutic areas including immunology, neuroscience, oncology, and Allergan Aesthetics as part of its mission.

Bullish Signals
  • Record net sales despite Humira loss.
  • CEO expects robust growth into 2026.
  • Pipeline advanced with strategic innovation investments.
  • Guidance for 2026 EPS set at $14.37-$14.57.
Risk Factors
  • 2026 EPS guidance excludes uncertain acquired IPR&D milestones.
  • Growth warnings cite IP challenges and adverse litigation risks.
  • Reconciling non-GAAP metrics distorts reliance on GAAP figures.
  • Net foreign exchange loss exposes earnings to currency drops.
  • No obligation to revise outlook leaves investors exposed.
Bullish Signals
  • AbbVie delivered record net sales in its second full year following the U.S. Humira loss of exclusivity, demonstrating strong performance from its diversified growth platform.
  • CEO Robert A. Michael described 2025 as another outstanding year and stated that the company expects robust growth to continue into 2026.
  • The company advanced promising new treatments and enhanced the breadth and depth of its pipeline through strategic investments in innovation.
  • AbbVie issued forward-looking guidance for full-year 2026 adjusted diluted EPS between $14.37 and $14.57, signaling confidence in future financial performance.
Risk Factors
  • AbbVie's adjusted diluted EPS guidance for full-year 2026 excludes any impact from acquired IPR&D and milestones, which may not be reliably forecasted and introduces significant uncertainty into future earnings projections.
  • The company explicitly warns that forward-looking statements regarding robust growth are subject to risks including challenges to intellectual property, competition from other products, and adverse litigation or government action.
  • Financial results are presented on both reported and non-GAAP bases, requiring investors to reconcile figures that adjust for certain non-cash items and unusual factors rather than relying solely on GAAP metrics.
  • Net foreign exchange loss is highlighted as a specific line item impacting earnings, indicating vulnerability to currency fluctuations.
  • AbbVie undertakes no obligation to revise its forward-looking statements based on subsequent events or developments, leaving investors exposed to unannounced material changes in the company's outlook.
Bullish +75

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

📈 Abbvie stock rose 5% on strong Q1 results beating earnings and revenue estimates.

💊 Key drugs Skyrizi/Rinvoq projected over $31B annual sales with imminent new approvals.

⚠️ Growth faces headwinds from Humira biosimilars, aesthetics softening, and pricing pressure.

📈 ABBV stock rose approximately 5% after reporting strong Q1 2026 results that beat earnings and revenue estimates.

🚀 Earnings per share increased 7.7% year-over-year while revenues grew 10.3% on an operational basis.

💰 The company raised its full-year 2026 EPS guidance from $13.96-$14.16 to a new range of $14.08-$14.28.

📉 Full-year 2026 revenue guidance was elevated from $67 billion to $67.3 billion following the robust quarter.

💊 Skyrizi and Rinvoq, key immunology drugs, significantly outperformed estimates with combined Q1 2025 sales of $6.6 billion.

🔮 AbbVie projects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026, representing over 20% growth.

💉 New regulatory approvals are imminent for Rinvoq, including potential indications for vitiligo, alopecia areata, hidradenitis suppurativa, and systemic lupus erythematosus.

🧠 Neuroscience sales surged 24.3% to $2.88 billion in Q1, driven by Botox Therapeutic, Vraylar, and new migraine medications.

⏳ Parkinson's drug Vyalev showed encouraging initial international uptake with expectations to reach blockbuster status in 2026.

🧬 The company maintains a robust oncology franchise featuring Imbruvica and Venclexta despite a slight 3% Q1 sales decline.

💉 A substantial pipeline is expected throughout 2026 with key readouts for candidates targeting metastatic colorectal cancer and multiple myeloma.

🤝 Management indicated strong financial capacity to continue the acquisition strategy in immunology, oncology, and neuroscience.

⚠️ AbbVie anticipates low single-digit pricing headwinds for Skyrizi and Rinvoq throughout 2026 and subsequent years.

🦾 Competitive pressure is mounting from J&J's new oral psoriasis pill Icotyde, though the company remains confident in navigating this challenge.

📉 Humira sales continue to decline due to biosimilar erosion, with a projected drop of around 50% in 2025 continuing into 2026.

💇 Aesthetics unit sales have softened due to macroeconomic challenges, with global projections expected to remain flat at $5 billion for 2026.

Bullish Signals
  • AbbVie Q1 2026 earnings rose 7.7% while revenues grew 10.3%.
  • Full-year EPS guidance raised to $14.08-$14.28, signaling strong confidence.
  • 2026 revenue guidance increased to $67.3 billion from previous $67 billion.
  • Skyrizi and Rinvoq generated $6.6B Q1 sales with >20% 2026 growth.
  • Rinvoq new indications could add roughly $2B to peak-year sales.
  • Neuroscience portfolio sales surged 24.3% to $2.88 billion driven by Vraylar and Botox.
  • Parkinson's franchise Vyalev holds over $5B in peak sales potential.
  • Robust pipeline includes lutikizumab readouts and regulatory submissions throughout 2026.
  • Management has capacity for M&A deals in immunology, oncology, and neuroscience.
Risk Factors
  • AbbVie expects low single-digit pricing headwinds for Skyrizi and Rinvoq beyond 2026.
  • Competitive pressure intensified by J&J's Icotyde threatens Skyrizi prescription trends.
  • Humira sales plummeted ~50% in 2025 due to biosimilar erosion.
  • Aesthetics sales projected flat at $5B in 2026 amid macro headwinds.
  • Juvederm sales face further decline due to dermal filler market headwinds.
  • Oncology sales declined 3% to $1.63B Q1 indicating franchise pressure.
Bullish Signals
  • AbbVie reported robust Q1 2026 results with earnings rising 7.7% year-over-year and revenues growing 10.3% on an operational basis.
  • The company raised its full-year EPS guidance from a range of $13.96-$14.16 to $14.08-$14.28, signaling strong confidence in future performance.
  • Guidance for 2026 total revenue was increased to $67.3 billion, exceeding the previous expectation of $67 billion.
  • Key immunology drugs Skyrizi and Rinvoq combined generated $6.6 billion in Q1 sales and are projected to deliver more than 20% growth in 2026 with expected combined sales exceeding $31 billion.
  • Rinvoq has potential for five new indications, including approvals expected for vitiligo and alopecia areata in 2026/early 2027, which could add roughly $2 billion to peak-year sales.
  • AbbVie's neuroscience portfolio showed strength with sales increasing 24.3% to $2.88 billion, driven by growth in Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, and the new Parkinson's drug Vyalev.
  • The Parkinson's disease franchise is viewed as a key growth driver with over $5 billion in peak sales potential for Vyalev and tavapadon.
  • AbbVie has a robust pipeline with expected data readouts for lutikizumab, Temab-A, and etentamig, alongside important regulatory submissions throughout 2026.
  • Management indicated significant financial capacity to pursue early and late-stage opportunities through M&A deals in immunology, oncology, and neuroscience.
  • AbbVie is evaluating Skyrizi-based combination regimens with candidates like ABBV-382 and ABBV-701 to create best-in-class durable remission therapies in IBD.
Risk Factors
  • AbbVie expects a low single-digit pricing headwind for its two flagship immunology drugs, Skyrizi and Rinvoq, in 2026 and beyond.
  • Competitive pressure has intensified with the launch of J&J's Icotyde oral pill for plaque psoriasis, which poses a direct threat to Skyrizi's prescription trends.
  • Sales of the company's largest revenue driver, Humira, have plummeted by approximately 50% in 2025 due to biosimilar erosion and continued exclusivity loss.
  • The Aesthetics division is facing soft sales driven by macroeconomic headwinds, with global aesthetics sales projected to be flat at $5 billion in 2026 despite new Botox growth.
  • Juvederm sales are expected to decline further as the company faces continued headwinds in key dermal filler markets.
  • Oncology sales have recently declined by 3% to $1.63 billion in Q1, indicating potential stagnation or pressure within that franchise.
Somewhat Bullish +40

AbbVie Inc. Just Missed Earnings - But Analysts Have Updated Their Models

📉 EPS fell sharply to $0.39, missing estimates by 69%.

💰 Revenue hit exactly $15b as expected by analysts.

🔮 2026 revenue projected to reach $67.4b with strong growth.

⚖️ Price target stays at $250 despite recent earnings miss.

⚠️ Company shows 5 warning signs and lags industry growth.

📉 AbbVie's quarterly statutory earnings per share fell sharply, missing estimates by 69% to reach US$0.39.

📈 Despite the earnings miss, the company's shares gained 4.0%, rising to US$207 on investor optimism.

💰 Revenue of US$15b came in exactly in line with analyst predictions for the latest quarter.

🔮 Analysts have updated their models to project 2026 revenues of US$67.4b, implying a 7.2% increase over the past 12 months.

⚡ Statutory earnings per share are predicted to surge by 318% to reach US$8.50 in 2026.

📊 The consensus price target remains largely unchanged at US$250 despite the recent results.

⚖️ There is a spread in analyst estimates with targets ranging from a low of US$184 to a high of US$294.

📉 AbbVie's forecast annualised revenue growth of 9.8% to 2026 is expected to significantly outpace its historical 5-year average of 2.0%.

⚠️ However, the company is still expected to grow meaningfully slower than the wider industry average, which is projected at 21% per year.

🧐 Overall sentiment remains stable as analysts have reconfirmed both earnings and revenue estimates for the future.

📈 Long-term analysis suggests the intrinsic value of the business has not undergone major changes with the latest data.

⚠️ A cautionary note indicates that AbbVie currently shows 5 warning signs in the investment analysis model.

Bullish Signals
  • AbbVie shares gained 4.0% to US$207 immediately following the release of its latest quarterly results.
  • The consensus forecast predicts that statutory earnings per share will jump 318% to US$8.50 by 2026.
  • Analyst estimates suggest a credible 7.2% revenue increase over the past 12 months, implying accelerated growth compared to the historical 2.0% annualised rate.
  • The consensus price target remained stable at US$250, indicating that analysts view the intrinsic value of the business as unchanged despite missing earnings.
  • Despite a miss in current statutory earnings, revenue came in line with analyst predictions at US$15 billion, demonstrating consistent top-line performance.
Risk Factors
  • Statutory earnings fell badly short, missing estimates by 69% to hit US$0.39 per share despite revenues being in line with predictions.
  • AbbVie is forecasted to grow revenue at 9.8% annually through 2026, which is significantly slower than the industry average of 21% per year.
  • Historical growth over the past five years has been merely 2.0% per annum, indicating long-term sluggishness compared to current acceleration.
  • Analyst sentiment remains split with a wide range in price targets, from US$184 for the most pessimistic view to US$294 for the most optimistic.
  • The company is identified as showing '5 warning signs' in its investment analysis framework.
  • No major change in analyst estimates following earnings suggests a lack of positive surprise despite the stock price gain.
Neutral 0

AbbVie Canada: AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

📅 AbbVie Canada honored RIME Therapeutics with a Quebec biotech award on April 30, 2026.

🏆 RIME received one year of lab space at adMare Innovation Centre in Montreal.

🤝 Program offers mentorship, equipment access, and support for early-stage life sciences companies.

💻 Recipients gain shared services from AbbVie scientific and business leaders.

🇨🇦 Initiative fosters globally competitive Canadian biotechs in immunology and oncology sectors.

📅 AbbVie Canada announced RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec on April 30, 2026.

🤝 The award is a collaboration between AbbVie and adMare BioInnovations to foster innovation within Quebec's life sciences sector.

🏆 RIME Therapeutics was recognized for its function-first disruptive approach merging target discovery with simultaneous hit identification.

💻 The award provides RIME with one year of laboratory and office space at the adMare Innovation Centre in Montreal.

⚙️ Recipients gain access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders.

🧬 RIME focuses on developing a peptide-based drug discovery platform targeting inflammation and immunology research.

🎯 The initiative supports early-stage biotech companies with potential in immunology, oncology, neuroscience, and aesthetics.

💬 Michael Mee, CEO of RIME Therapeutics, stated the award supports their path from novel biology to tractable chemistry.

🗣️ Matthew Carlyle, President and CEO of adMare BioInnovations, highlighted the focus on creating globally competitive Canadian life sciences companies.

🇨🇦 Stéphanie Sauvageau, Head of Medical at AbbVie Canada, emphasized commitment to fostering a thriving life sciences ecosystem in Quebec.

🔬 RIME Therapeutics was founded in 2025 as a Montreal-based start-up focused on protein-protein interaction targets.

⚠️ The program aims to accelerate scientific innovation and address pressing health challenges facing Canadians.

💼 adMare BioInnovations has helped create 39 companies with a combined value of $5.8 billion through its life sciences engine model.

🏢 AbbVie's therapeutic areas include immunology, oncology, neuroscience, eye care, and Allergan Aesthetics products.

Bullish Signals
  • AbbVie recognizes RIME with Biotech Innovators Award for Quebec innovation.
  • RIME receives full year of Montreal lab space and shared equipment.
  • Award includes mentorship from AbbVie leaders to advance peptide drug discovery.
  • adMare partners have spawned 39 companies, attracting $2.5B in capital.
  • Program supports early-stage biotech in immunology, oncology, neuroscience, and aesthetics.
  • RIME targets novel T cell biology for differentiated medicine pipeline.
  • CEO confirms partnership provides world-class infrastructure to scale Canadian biotech.
Bullish Signals
  • AbbVie has recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, highlighting its commitment to fostering innovation in Quebec's life sciences sector.
  • RIME Therapeutics will receive a full year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to shared equipment and services to accelerate research.
  • The award includes mentorship from AbbVie's scientific and business leaders to help advance RIME's peptide-based drug discovery platform for inflammation and immunology diseases.
  • adMare BioInnovations has created 39 companies that have attracted $2.5 billion in risk capital, achieved a combined value of $5.8 billion, and created approximately 1,000 jobs through its life sciences model.
  • The AbbVie Biotech Innovators Award supports early-stage biotechnology companies focused on AbbVie's key therapeutic areas including immunology, oncology, neuroscience, and aesthetics.
  • RIME Therapeutics aims to address novel T cell biology with broad therapeutic applicability, merging target discovery with simultaneous hit identification for differentiated pipeline of medicines.
  • Matthew Carlyle, President and CEO of adMare BioInnovations, noted the partnership provides access to world-class infrastructure, expertise and mentorship to help Canadian biotech companies build value and scale.
Somewhat Bullish +50

AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings

📉 AbbVie stock remained sluggish early 2026 despite strong Q1 fundamentals.

📈 Q1 revenue grew double-digits with healthy adjusted earnings per share.

💰 Attractive dividend yield and improved market multiples support long-term value.

📉 AbbVie's stock price remained sluggish in early 2026 despite underlying fundamentals.

💼 Potential acquisition rumors are circulating, which currently weigh on earnings sentiment but could boost long-term revenue.

📈 Q1 2026 results showed double-digit percentage revenue growth and a healthy increase in adjusted earnings per share.

🏦 Market multiples for the company have improved compared to previous valuations.

💰 AbbVie's dividend yield remains attractive and suggests strong long-term investor potential.

👩‍💼 Analyst Manika, a macroeconomist with 20 years of experience, authored the article under her profile Long Term Tips.

⚠️ Stock price corrections were expected earlier due to the MFN agreement signing and elevated market multiples.

🔍 The report notes that acquisition activity is an earnings drag in the short term but positive for revenues eventually.

📝 The author disclosed no stock positions or compensation plans related to the companies mentioned in the article.

⚖️ Seeking Alpha provided a standard disclaimer regarding investment advice and third-party author credentials.

🌱 The content is part of a broader focus on generational opportunities in the green economy via Green Growth Giants.

Bullish Signals
  • Revenue grew double-digit percent in Q1 2026.
  • Adjusted EPS increased during first quarter 2026.
  • Market multiples improved showing investor interest.
  • Dividend yield remains attractive for income.
  • Long-term outlook is strong with earnings quality.
Risk Factors
  • sentence.
  • Stock price sluggish in 2026 despite earnings growth.
  • points.
  • sentence.
  • Acquisition talk drags near-term earnings and shares.
  • points.
  • sentence.
  • Price correction occurred after MFN agreement signing.
  • points.
  • sentence.
  • Elevated market multiples suggest overvaluation or caution.
  • points.
Bullish Signals
  • AbbVie (ABBV) posted positive Q1 2026 earnings results, delivering double-digit percent revenue growth.
  • The company also achieved a healthy rise in adjusted EPS during the first quarter of 2026.
  • Market multiples for AbbVie have improved, indicating renewed investor interest and valuation support.
  • AbbVie's dividend yield is encouraging, providing an attractive income component alongside capital appreciation potential.
  • Long-term outlook looks strong as current earnings quality supports investor retention over time.
Risk Factors
  • The stock's price has been sluggish in 2026 so far, indicating potential continued weakness despite positive earnings.
  • Acquisition talk surrounding the company is acting as an earnings drag in the near term, potentially suppressing share performance.
  • A price correction was previously on the cards when the company was due to sign the MFN agreement, which has now played out.
  • Market multiples were elevated at the time of the potential acquisition signing, suggesting possible overvaluation or investor caution.
Slightly Bullish +25

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

🏆 RIME Therapeutics won AbbVie's Biotech Innovators Award in Quebec.

🧪 The prize provides lab space, equipment access, and executive mentorship.

🚀 RIME develops AI-driven peptide drugs targeting inflammation and immunology.

🌍 This initiative aims to scale Canada's global life sciences ecosystem.

🏆 AbbVie and adMare BioInnovations announced RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec.

🌍 The award recognizes national competition winners to foster innovation within Quebec's life sciences sector.

🎓 RIME Therapeutics will receive one year of laboratory and office space at the adMare Innovation Centre in Montreal.

🧪 The prize includes access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders.

🔬 Founded in 2025, RIME Therapeutics is developing a peptide-based drug discovery platform for inflammation and immunology.

🚀 RIME's Disruptide Platform merges target discovery with simultaneous hit identification to address novel T cell biology.

💰 The award targets early-stage biotech companies aligning with AbbVie's focus areas like immunology, oncology, neuroscience, and aesthetics.

🤝 Michael Mee, CEO of RIME Therapeutics, expressed honor in receiving the award to accelerate their path from novel biology to tractable chemistry.

📈 Matthew Carlyle, President and CEO of adMare BioInnovations, highlighted the partnership's focus on scaling globally competitive Canadian companies.

⚕️ Stéphanie Sauvageau, Head of Medical at AbbVie Canada, emphasized commitment to fostering a thriving life sciences ecosystem across Canada.

🔍 RIME Therapeutics integrates human genetics, perturbation biology, and AI to scan functional drug pocket space.

💼 adMare BioInnovations has helped create 39 companies that attracted $2.5 billion in risk capital and created approximately 1,000 jobs.

🏢 adMare provides over 200,000 square feet of turnkey lab facilities to support Canadian life science scaling.

📅 The announcement was made on April 30, 2026, according to the Globe NewsWire.

📍 RIME Therapeutics is based in Montreal and aims to build a differentiated pipeline of medicines for patients.

Bullish Signals
  • AbbVie has established a strong commitment to fostering innovation in Quebec's life sciences sector by launching the AbbVie Biotech Innovators Award.
  • The award provides RIME Therapeutics, a Montreal-based startup founded in 2025, with a full year of laboratory and office space at the adMare Innovation Centre.
  • RIME Therapeutics will gain access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders, accelerating its drug discovery platform.
  • RIME's Disruptide Platform addresses a persistent challenge in drug discovery by merging target discovery with simultaneous hit identification.
  • The initiative aligns with AbbVie's strategic focus on immunology, oncology, neuroscience, and aesthetics, potentially expanding its therapeutic pipeline.
  • Partner adMare BioInnovations has a proven track record of creating 39 companies that have attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion.
  • adMare supports early-stage innovation with over 200,000 square feet of turnkey lab facilities, demonstrating robust infrastructure capacity for growth.
Risk Factors
  • No negative aspects or risks were identified in this article; the content focuses entirely on positive achievements, partnerships, and strategic awards.
Bullish +75

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

📈 Q1 revenue beat consensus driven by skyrockets Skyrizi, Rinvoq, and migraine drugs.

🧬 Management raised EPS guidance despite GAAP impact from a strategic IPR&D charge.

⚠ Legacy Humira faces biosimilar pressure while new obesity pipeline awaits readout.

💸 Stock remains undervalued with strong buy ratings after significant year-to-date decline.

📈 AbbVie reported Q1 revenue of $15 billion, beating the $14.72 billion consensus by $280 million.

🧬 Star drugs Skyrizi and Rinvoq drove strong growth, with Skyrizi up 30.9% and Rinvoq up 23.3% year-over-year.

💊 The migraine franchise surged with Qulipta growing 53.6% and Ubrelvy up 41.4%.

🚀 Management raised full-year adjusted EPS guidance to $14.08–$14.28 despite a slight GAAP miss.

⚖️ Shares are currently down 9.3% year-to-date after a 9.3% drop since the end of last year.

💡 The obesity pipeline candidate ABBV-295 showed early clinical benefit in body weight reduction data.

🎯 Oncology drug Elahere demonstrated a greater than 60% objective response rate in platinum-sensitive ovarian cancer.

⬇️ Biosimilar pressure weighs on legacy drugs like Humira, which fell 38.6% to $688 million in revenue.

💸 A $744 million IPR&D charge impacted GAAP earnings but is viewed as a strategic investment rather than core weakness.

👍 Wall Street consensus sees 22 buy ratings versus zero sells, with a price target of $249.27.

📈 Analysts see a high confidence buy rating due to strong growth franchises and compressed valuation multiples.

⚠️ Risks include potential deceleration in immunology growth and additional FDA Complete Response Letters on manufacturing.

💰 The company's forward multiple has compressed to reasonable levels following the stock's decline.

🔮 The obesity pipeline readout later in the year is a key factor that could impact future returns.

👨‍⚕️ CEO Robert Michael confirmed that key growth drivers are delivering strong performance supporting the enhanced outlook.

Bullish Signals
  • AbbVie revenue beat by $280M to $15B.
  • Skyrizi sales surged 30.9% YoY.
  • Rinvoq growth reached 23.3% to $2.12B.
  • Full-year EPS guidance raised to $14.08-$14.28.
  • Migraine franchise grew: Qulipta +53.6%, Ubrelvy +41.4%.
  • Obesity candidate ABBV-295 showed weight reduction.
  • Elahere achieved >60% response rate in trials.
  • Price target $249.27 with 22 buy ratings.
  • Stock closed up 3.14% on earnings.
Risk Factors
  • AbbVie missed EPS estimates by $0.02 despite revenue beats.
  • A $744M IPR&D charge reduced earnings per share by $0.41.
  • GAAP net income dropped 45.96% YoY due to significant charges.
  • Humira revenue fell 38.6% and Imbruvica slid 24.7%.
  • FDA issued a Complete Response Letter over manufacturing issues.
  • Growth relies on Skyrizi and Rinvoq avoiding deceleration.
  • Valuation risks include more CR letters or biosimilar competition.
  • U.S. pricing policy shifts could compress margins for key drugs.
  • Phase 2 success of ABBV-295 is a critical growth assumption.
Bullish Signals
  • AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus estimates by $280M.
  • Skyrizi sales surged 30.9% year-over-year to $4.48B and Rinvoq grew 23.3% to $2.12B.
  • Management raised full-year adjusted EPS guidance to a range of $14.08-$14.28, signaling confidence in the company's outlook.
  • The migraine franchise showed exceptional growth with Qulipta up 53.6% and Ubrelvy up 41.4%.
  • The obesity pipeline candidate ABBV-295 demonstrated clinically meaningful body weight reduction in early clinical data.
  • Oncology drug Elahere achieved a >60% objective response rate in platinum-sensitive ovarian cancer trials.
  • Wall Street consensus price targets stand at $249.27 with 22 buy ratings and zero sells.
  • The company's stock closed up 3.14% following the earnings report, reflecting investor optimism.
Risk Factors
  • AbbVie's Adjusted EPS of $2.65 missed consensus estimates by $0.02, despite headline revenue beats.
  • The company recorded a massive $744 million charge for in-process research and development (IPR&D), which clipped earnings per share by $0.41.
  • GAAP net income fell sharply by 45.96% year-over-year, reflecting significant accounting charges rather than just core operational weakness.
  • Major revenue franchises are declining: Humira revenue plummeted 38.6% YoY to $688 million, and Imbruvica slid 24.7%. These losses could continue if growth from new drugs like Skyrizi and Rinvoq stalls.
  • Regulatory risks remain high, with the FDA issuing a Complete Response Letter on trenibotulinumtoxinE specifically over manufacturing issues, setting a precedent for future approval hurdles.
  • Future projections rely heavily on Skyrizi and Rinvoq maintaining robust growth; any material deceleration in these immunology drugs would undermine the bull case.
  • Valuation concerns could escalate if additional Complete Response Letters emerge across other portfolio segments or if biosimilar competition intensifies later in the decade.
  • Significant downside risks include potential shifts in U.S. drug pricing policy, which could compress margins for key franchises like Skyrizi and Rinvoq.
  • The successful progress of the obesity candidate (ABBV-295) through Phase 2 is a critical assumption; failure here would negatively impact the growth pipeline.
Bullish +75

Here are Thursday's biggest analyst calls: Nvidia, Amazon, Microsoft, Meta, Alphabet, Palantir, AbbVie & more

📈 Analysts upgrade Equinix, Palantir, and Microsoft citing strong AI demand and growth.

🔍 JPMorgan raises Alphabet target while downgrading Meta over intensifying AI competition.

💊 Bank of America upgrades AbbVie, Nutrien, and Amazon on earnings strength.

📈 Raymond James upgrades Equinix (EQIX) from outperform to strong buy following Q1 2026 results and AI-based demand.

💧 Deutsche Bank upgrades SiteOne Landscape to buy, citing a low valuation that implies 32% upside from their $160 price target.

🛡️ Roth Capital initiates coverage on Mistras with a buy rating and $22 price target due to improved operating efficiency.

🤖 Bank of America reiterates Nvidia (NVDA) as a buy, maintaining a $300 price target based on 28x CY27E PE.

💻 Oppenheimer initiates coverage of Palantir (PLTR) with an outperform rating and $200 price target.

📊 Baird upgrades Blackbaud to outperform from neutral after a solid Q1 beat and steady customer retention.

🔌 JPMorgan upgrades Teradyne to overweight following a stock pullback driven by lumpiness in customer purchasing.

⚠️ JPMorgan downgrades Meta (META) from overweight to neutral due to intensifying full-stack AI competition.

🌾 Bank of America upgrades Nutrien to buy, viewing the agriculture market as increasingly bullish.

💊 Bank of America upgrades AbbVie (ABBV) to buy from neutral, dismissing competition fears and citing strong immunology brand growth.

☁️ Morgan Stanley reiterates Microsoft as overweight, praising agentic computing expansion and AI-driven margin improvements.

🛒 Bank of America raises its Amazon price target to $310 from $298 following earnings on strong eCommerce and cloud assets.

🔍 JPMorgan raises Alphabet's price target to $460 from $395, citing clear returns on AI investments and doubled cloud backlog.

📰 Wells Fargo reiterates Meta as overweight, noting robust ad growth despite macro headwinds in the Middle East.

📱 Qualcomm receives a neutral hold from JPMorgan due to Q2 earnings beat but weak Q3 guidance influenced by smartphone headwinds.

Bullish Signals
  • Bank of America upgrades AbbVie (ABBV) to Buy.
  • Growth warrants a premium multiple near top peers.
  • Core immunology brands show strong and durable prospects.
  • Pipeline efforts create significant upside potential.
  • Limited portfolio headwinds identified for the next 7 years.
Risk Factors
  • JPMorgan downgraded Meta as AI costs pressure returns amid competition.
  • Wells Fargo says Meta growth catalysts are delayed to next year.
  • Qualcomm missed guidance due to smartphone headwinds and shipment concerns.
  • Middle East conflict hurts Meta ad growth while product rollout delays.
Bullish Signals
  • Bank of America upgrades AbbVie to a Buy from Neutral, signaling confidence that competition fears are overdone.
  • Analysts at Bank of America rate ABBV as having a premium multiple well warranted given growth near the top of the peer group.
  • The firm sees strong and durable growth prospects in core immunology brands despite increasing competition.
  • There is significant upside potential tied to AbbVie's robust pipeline efforts according to Bank of America.
  • Bank of America identifies limited identifiable portfolio headwinds in the next 7 years for the stock.
Risk Factors
  • JPMorgan downgraded Meta from overweight to neutral due to rising competition and concerns that a full-stack AI intensifies pressure, making it harder for Meta to generate returns on heavy AI capital expenditures.
  • Wells Fargo noted that product catalysts for Meta seem pushed to the second half of the year, delaying the path to aggressive growth while operating expense ramp-up continues.
  • JPMorgan raised concerns about Qualcomm facing headwinds in the smartphone industry that drove its third-quarter guidance to track below consensus, partly due to expectations of another quarter of under-shipping relative to end customers.
  • The outlook for Meta includes macro headwinds related to the Middle East conflict impacting ad growth, with product catalysts delayed until later in the year.
Bullish +75

AbbVie Q1 Earnings Call Highlights

📈 AbbVie Q1 adjusted EPS $2.65 and revenue $15B, both exceeding analyst expectations.

🧬 Immunology leaders SKYRIZI and RINVOQ drove growth with double-digit gains across portfolios.

⚠ HUMIRA global sales fell 40.3% operationally due to biosimilar competition.

📈 AbbVie reported Q1 adjusted EPS of $2.65 and revenue of $15.0 billion, exceeding analyst expectations.

💰 Full-year adjusted EPS guidance was raised to $14.08–$14.28 with 2026 net revenue expected at approximately $67.3 billion.

🧬 Immunology portfolio showed strong momentum, with SKYRIZI generating $4.5B (+29%) and RINVOQ generating $2.1B (+20%).

🧠 Neuroscience products including VRAYLAR, the migraine portfolio, and VYALEV all posted double-digit growth gains.

💉 Phase III data for SKYRIZI in Crohn’s was positive, and an obesity candidate (ABBV‑295) showed nearly 10% weight loss at 12 weeks.

⚖️ AbbVie raised expectations for global SKYRIZI revenue to $21.6B and RINVOQ sales to $10.2B based on expanded indications.

🧠 Neuroscience total revenues were revised up to $12.6 billion, driven by momentum across the portfolio.

💊 Oncology revenues totaled over $1.6 billion, slightly down 3% operationally, with VENCLEXTA sales increasing 9.7%.

🧴 Aesthetics business revenue rose 5.1% to nearly $1.2 billion, led by a 17% increase in BOTOX Cosmetic sales.

⚠️ HUMIRA global sales declined 40.3% operationally due to biosimilar competition but remained within management expectations.

📉 R&D expenses included a $0.41 unfavorable impact from acquired in-process R&D, though adjusted gross margins remained at 83.6%.

✅ CEO Rob Michael described the quarter as an "excellent start" with performance exceeding expectations across the diverse portfolio.

🔬 Chief Scientific Officer Roopal Thakkar highlighted positive AFFIRM study data for SKYRIZI in Crohn’s disease induction.

Bullish Signals
  • AbbVie Q1 adjusted EPS hit $2.65, beating guidance by $0.07.
  • Net revenues reached $15B, surpassing estimates and growing 12.4%.
  • Full-year adjusted EPS guidance raised to $14.08–$14.28.
  • CEO Rob Michael says the company started the year excellently.
  • Immunology segment grew strongly with SKYRIZI sales at $4.5B.
  • SKYRIZI expects global revenues of $21.6B amid demand growth.
  • FDA approved adding genital and scalp psoriasis results to SKYRIZI label.
  • RINVOQ global sales reached $2.1B, up 20.2% operationally.
  • Neuroscience segment revenue rose to nearly $2.9B, up 24.3%.
  • AbbVie raised full-year neuroscience revenue expectations to $12.6B.
  • RINVOQ sales expectations raised to $10.2B globally.
  • Parkinson's therapy VYALEV projected blockbuster sales of $201M.
  • Oncology revenues resilient with VENCLEXTA sales at $770M.
  • AbbVie expects total net revenues of $67.3B for 2026.
  • Aesthetics business posted global sales of nearly $1.2B.
Risk Factors
  • HUMIRA sales down 40.3% from biosimilar competition.
  • IMBRUVICA revenue down 24.7% due to IRA pricing.
  • JUVÉDERM sales fell 2.9% amid market inflation dynamics.
  • Q1 EPS hit by $0.41 IPR&D expense impact.
  • Guidance omits future IPR&D expense estimates creating uncertainty.
  • Tavapadon approval delayed until late 2026, not immediate.
  • SKYRIZI Crohn's study only met partial endpoints.
Bullish Signals
  • AbbVie reported Q1 adjusted EPS of $2.65, which exceeded expectations by $0.07 above the midpoint of guidance.
  • Total net revenues reached $15.0 billion, beating analyst estimates by $300 million and reflecting sales growth of 12.4%.
  • Management raised full-year adjusted EPS guidance to a range of $14.08–$14.28, up $0.12 from the previous estimate.
  • CEO Rob Michael stated the company is 'off to an excellent start to the year' with performance exceeding expectations across its diverse portfolio.
  • Immunology segment drove strong growth with SKYRIZI reaching $4.5 billion in sales, up 29% operationally and gaining share in psoriatic and IBD indications.
  • SKYRIZI now expects global revenues of $21.6 billion, an increase of $100 million driven by demand growth in psoriatic and inflammatory bowel disease (IBD).
  • The FDA approved adding new results to the SKYRIZI label for genital and scalp psoriasis following data presented at the American Academy of Dermatology meeting.
  • RINVOQ global sales reached $2.1 billion, up 20.2% operationally, with a noted inflection in gastroenterology prescriptions for ulcerative colitis.
  • Neuroscience segment generated nearly $2.9 billion in revenue, up 24.3% operationally, with migraine portfolio growth driving the increase.
  • AbbVie raised expectations for total neuroscience revenues to $12.6 billion for the full year, an increase of $100 million.
  • RINVOQ sales expectations were raised to $10.2 billion globally, reflecting strong performance in rheumatology and gastroenterology.
  • Parkinson's therapy VYALEV is on track to become a blockbuster with sales of $201 million, up about 10% sequentially.
  • Oncology revenues showed resilience with VENCLEXTA sales reaching $770 million, up 9.7% operationally supported by emerging combination use.
  • AbbVie expects total net revenues of approximately $67.3 billion for 2026, an increase of $300 million from previous guidance.
  • The aesthetics business posted global sales of nearly $1.2 billion, up 5.1% operationally, with BOTOX Cosmetic revenue rising 17% to $668 million.
Risk Factors
  • AbbVie's HUMIRA global sales declined 40.3% operationally due to biosimilar competition, marking a significant revenue headwind despite expectations of being in line.
  • IMBRUVICA oncology product saw revenue decline 24.7% operationally due to IRA pricing reductions and competitive pressure in the market.
  • JUVÉDERM sales fell 2.9% amid continued headwinds in key dermal filler markets, attributed to lingering inflationary dynamics rather than a recession.
  • First-quarter adjusted EPS included a $0.41 unfavorable impact from acquired in-process R&D (IPR&D) expense, reducing reported profitability.
  • The full-year guidance does not include any estimate for acquired IPR&D expense that may occur beyond the first quarter, creating uncertainty about future quarterly results.
  • Neuroscience revenues expectations face potential risk as tavapadon faces a delayed timeline with a potential U.S. approval expected later in 2026 instead of immediate launch.
  • SKYRIZI phase III AFFIRM study data for Crohn's disease subcutaneous induction only met endpoints, requiring ongoing clinical validation to support expanded indications.
Bullish +73

Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside

📈 AbbVie shares up ~2% premarket after positive Q1 results.

💰 Revenue beat expectations, boosting full-year earnings outlook.

🏆 Quant Rating ranks AbbVie near top of biotech stocks.

📊 Strong fundamentals and scale drive stable investment thesis.

⚠ Analysts highlight upside potential for large-cap pharma leader.

📈 AbbVie (ABBV) shares rose approximately 2% in premarket trading following positive first-quarter results.

💰 The pharmaceutical giant exceeded revenue expectations for the first quarter, driving a strong financial performance.

🚀 Management raised its full-year earnings outlook based on the robust Q1 beat and improved market conditions.

🏆 Seeking Alpha ranks AbbVie near the top of biotech stocks based on its Quant Rating system.

📊 The company demonstrates strength through scale, diversification, and solid fundamentals compared to peers.

🧠 Quant Ratings evaluate ABBV's value using metrics like valuation, growth, momentum, and profitability.

🔍 Analysts view AbbVie as presenting a compelling fundamental case among top-rated biotech companies.

📉 The investment thesis highlights ABBV's position as a stable large-cap pharma stock with upside potential.

Bullish Signals
  • AbbVie raised full-year earnings outlook after strong Q1 revenue beat.
  • Shares up ~2% premarket, showing market confidence in performance.
  • Company ranks near top of biotech by scale and fundamentals.
  • Seeking Alpha Quant Ratings confirm compelling buy-case among peers.
Risk Factors
  • No negative points mentioned.
  • No downsides or risks included.
Bullish Signals
  • AbbVie raised its full-year earnings outlook following a strong first-quarter revenue beat, signaling robust financial momentum.
  • Shares climbed roughly 2% in premarket trading after the positive Q1 results, demonstrating immediate market confidence in the company's performance.
  • The company sits near the top of biotech rankings based on its scale, diversification, and robust fundamentals compared to peers.
  • Seeking Alpha's Quant Ratings confirm AbbVie presents a compelling fundamental case among top Buy-rated biotech stocks.
Risk Factors
  • The article is overwhelmingly positive, highlighting a Q1 revenue beat and raised full-year earnings outlook, leaving no explicit negative points or risks mentioned in the provided text.
  • No specific concerns such as competitive threats, regulatory issues, declining metrics, or downside catalysts were included in this news summary.
Bullish +75

AbbVie (ABBV) Stock Jumps on Strong Q1 Beat and Upgraded Full-Year Forecast

📈 AbbVie beat estimates with Q1 adjusted EPS of $2.65 and $15B revenue.

💊 Skyrizi and Rinvoq drove growth despite a 39% Humira decline.

🚀 Immunology rose 16%, neuroscience surged 26%, and full-year forecast was upgraded.

📉 Stock remains down 13% YTD but adjusted earnings improved for two quarters.

📈 AbbVie reported first-quarter adjusted earnings of $2.65 per share, beating analyst estimates of $2.59.

💰 Total quarterly revenue reached $15 billion, representing a 12% year-over-year increase.

🚀 The immunology division grew by 16%, while the neuroscience segment surged by 26%.

💊 Skyrizi and Rinvoq drove growth with revenue increases of 31% and 23% respectively.

⚠️ Strong performance from new products offset a 39% revenue decline in Humira due to biosimilar competition.

📈 ABBV shares rose 2.5% in premarket trading following the positive earnings announcement.

🔭 The company raised its full-year 2026 adjusted EPS forecast to $14.08–$14.28.

🤝 Upgraded guidance reflects management confidence in the immunology and neuroscience portfolios.

⚖️ GAAP net income declined year-over-year to $0.39 per share due to excluded expenses not captured in adjusted metrics.

📉 Despite the stock recovering some losses, it still faces a 13% year-to-date decline.

🧠 Neuroscience is establishing itself as an increasingly important revenue source for the company.

🔁 Adjusted earnings of $2.65 mark the second consecutive quarter of year-over-year improvement.

Bullish Signals
  • Adjusted EPS reached $2.65, surpassing the $2.59 consensus.
  • Revenue hit $15 billion, a strong 12% year-over-year increase.
  • Immunology segment grew 16%, driven by Skyrizi and Rinvoq gains.
  • Neuroscience segment surged 26%, proving successful diversification success.
  • Raised full-year 2026 EPS forecast range to $14.08–$14.28.
Risk Factors
  • Shares down 13% YTD despite strong earnings.
  • Humira revenue dropped 39% amid biosimilar competition.
  • GAAP net income fell to $695 million.
  • EPS guidance offers little room for error.
  • Stock must recover 13% decline before momentum.
Bullish Signals
  • AbbVie reported first-quarter adjusted earnings of $2.65 per share, surpassing the analyst consensus estimate of $2.59 and climbing from $2.46 in the same period last year.
  • Quarterly revenue reached $15 billion, representing a strong 12% year-over-year increase that beat the $14.72 billion analyst projection.
  • The immunology division grew by 16%, driven by Skyrizi's 31% revenue increase and Rinvoq's 23% growth, successfully offsetting the decline in the Humira franchise.
  • The neuroscience segment delivered an impressive 26% quarterly surge, demonstrating successful diversification beyond the immunology business.
  • Management raised its full-year 2026 adjusted EPS forecast to a range of $14.08–$14.28, upgrading from the previous $13.96–$14.16 range and placing the midpoint above Wall Street consensus.
  • Shares of ABBV gained 2.5% in premarket trading to reach $202.63 as investors responded favorably to the earnings beat and upgraded guidance.
  • AbbVie has achieved two consecutive quarters of year-over-year adjusted earnings improvement, with Q1 results decisively beating the prior-year figure.
Risk Factors
  • Despite strong earnings, AbbVie shares are still down 13% year-to-date as of Tuesday's market close, indicating significant recent investor skepticism or broader market headwinds.
  • The company faces a severe structural risk from Humira, which saw a steep 39% revenue drop as it loses market share to competitive biosimilar alternatives.
  • On a GAAP basis, quarterly net income totaled only $695 million ($0.39 per diluted share), representing a significant year-over-year decline compared to the prior year's $1.29 billion.
  • Full-year 2026 adjusted EPS guidance of $14.08–$14.28 places the company right at or near Wall Street consensus estimates, leaving little room for error given the high valuation implied by recent premarket gains.
  • The stock needs to make up considerable lost ground from its 13% year-to-date decline before any short-term momentum translates into sustained value.
Somewhat Bullish +50

Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?

💊 AbbVie replaced Humira revenue with Skyrizi/Rinvoq generating $26B in 2025.

📈 Pfizer oncology revenues rose 8% following Seagen acquisition despite flat COVID outlook.

⚠ Both companies face patent cliffs and pipeline headwinds ahead of 2026.

💰 AbbVie offers strong earnings growth potential with 45.3% estimated increase for 2026.

📉 Pfizer trade at lower P/E ratio but faces declining sales expectations in 2026.

🏥 AbbVie and Pfizer are two leading U.S. drugmakers with diverse portfolios across oncology, immunology, neuroscience, and vaccines.

💊 AbbVie offset Humira's loss of exclusivity with newer immunology therapies Skyrizi and Rinvoq, which now generate about half of its revenue.

🔬 Both companies have robust R&D pipelines intended to drive innovation and long-term growth in their respective sectors.

🧬 Pfizer strengthened its oncology position with the 2023 Seagen acquisition, contributing to an 8% revenue increase in 2025.

💉 Pfizer's non-COVID revenues are improving driven by products like Vyndaqel, Padcev, and Eliquis, with recently acquired products rising 14% in 2025.

🤝 Pfizer invested approximately $9 billion in M&A deals in 2025 to rebuild its pipeline, including acquisitions of Metsera and licensing from 3SBio.

🧪 Pfizer plans 20 pivotal studies in 2026, including ten for obesity candidates from the Metsera acquisition.

⚠️ Pfizer's 2026 outlook shows mostly flat to slightly negative growth due to declining COVID sales, Medicare Part D impacts, and upcoming patent expirations.

📉 The Zacks Consensus Estimate for Pfizer's 2026 implies a year-over-year decrease of 2.5% in sales and 7.5% in earnings.

💰 Pfizer offers an impressive dividend yield of around 6.3% alongside significant cost reduction efforts to improve R&D productivity.

📈 AbbVie's Skyrizi and Rinvoq combined sales reached $26 billion in 2025, growing over 40%, with expectations for more than $31 billion in 2026.

🧠 AbbVie's neuroscience portfolio saw a 20% sales increase to $10.8 billion in 2025, driven by Botox Therapeutic and migraine drugs Ubrelvy and Qulipta.

🔬 AbbVie invested over $5 billion in 2025 for M&A deals to bolster its pipeline in immunology, oncology, and neuroscience.

⚠️ AbbVie faces near-term headwinds including Humira biosimilar erosion, slowing oncology sales, and a 5.9% decline in aesthetics portfolio sales.

📊 The Zacks Consensus Estimate for AbbVie's 2026 implies a 9.6% sales increase and 45.3% earnings growth compared to the previous year.

📉 Pfizer stock has risen 24.2% over the past year, while AbbVie jumped 21.3%, outperforming or matching industry returns of 25.8%.

📉 AbbVie trades at a lower forward P/E ratio of 14.14 compared to Pfizer's 9.29 and the industry average of 17.42.

Bullish Signals
  • AbbVie immunology therapies grew sales $26B in 2025 with over 40% YoY growth.
  • Skyrizi and Rinvoq sales expected to exceed $31B in 2026.
  • Neuroscience portfolio sales rose 20% to $10.8B in 2025 driven by key drugs.
  • Pfizer dividend yield reaches 6.3% with oncology revenue growth of 8% in 2025.
  • Pfizer invested $9B in M&A deals including Metsera acquisition for pipeline depth.
  • AbbVie invested over $5B in 2025 to acquire innovative pipeline candidates.
  • Zacks Consensus predicts AbbVie 2026 earnings increase of 45.3%.
  • Pfizer expects double-digit growth in 2026 with 10 pivotal obesity studies planned.
Risk Factors
  • Pfizer guidance shows flat to negative growth for 2026.
  • Pfizer sales decline due to COVID drugs, Medicare Part D, and patent expirations until 2030.
  • AbbVie faces biosimilar erosion, oncology slowdown, and a 5.9% aesthetics sales drop in 2025.
  • AbbVie consensus earnings estimate fell from $16.15 to $16.14 per share over 60 days.
  • AbbVie shares trade above five-year mean of 13.81, signaling valuation concerns.
Bullish Signals
  • AbbVie successfully offset the impact of Humira's loss of exclusivity with its newer immunology therapies Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 representing year-over-year growth of more than 40%.
  • In 2026, AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion, signaling strong top-line growth prospects for its core immunology business.
  • AbbVie's neuroscience portfolio contributed significantly to top-line growth with sales increasing almost 20% to $10.8 billion in 2025 driven by Botox Therapeutic, Vraylar, and newer migraine drugs Ubrelvy and Qulipta.
  • Pfizer achieved an impressive dividend yield of around 6.3%, providing attractive income potential for investors while maintaining strong positions in oncology with its acquired products driving 8% revenue growth in 2025.
  • Pfizer invested around $9 billion in M&A deals in 2025 including the acquisition of Metsera and licensing from 3SBio, which adds ultra-long-acting obesity candidates and pipeline depth for future innovation.
  • AbbVie invested more than $5 billion in 2025 to acquire innovative pipeline candidates, demonstrating a strong commitment to bolstering its early-stage pipeline for long-term growth.
  • The Zacks Consensus Estimate for AbbVie's 2026 earnings shows a year-over-year increase of 45.3%, reflecting robust market expectations despite some near-term headwinds.
  • Pfizer expects its recently launched and acquired products to record continued double-digit growth in 2026, including specific plans to start 20 pivotal studies that include 10 for obesity candidates from the Metsera acquisition.
Risk Factors
  • Pfizer's 2026 revenue and earnings guidance failed to impress investors, representing mostly flat to slightly negative growth.
  • Pfizer faces declining sales of its COVID products, unfavorable impact from Medicare Part D redesign, and upcoming patent expirations for key products like Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi in the 2026-2030 period.
  • AbbVie faces near-term headwinds including Humira's biosimilar erosion, a slight slowdown in oncology sales, and declining sales of its Aesthetics unit due to macro challenges with a 5.9% decline in global sales in 2025.
  • The Zacks Consensus Estimate for AbbVie's 2027 earnings has decreased from $16.15 to $16.14 per share over the past 60 days, indicating weakening market expectations.
  • AbbVie's shares currently trade higher than its five-year mean of 13.81, suggesting potential valuation concerns despite trading at 14.14 forward earnings.
Neutral 0

Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more

📅 Published April 10, 2026, this dividend roundup by Seeking Alpha highlights key payouts.

📈 Agree Realty increases dividend payout for the current week's coverage period.

🏥 AGNC, Healthpeak, and major players like AbbVie announce upcoming dividend declarations.

🏦 Related ETFs DVY and VYM tracked alongside these income-generating stock activities.

📅 This dividend roundup article was published on April 10, 2026, by Seeking Alpha News Editor Sinchita Mitra.

🏢 It highlights recent dividend activities from several companies including AGNC Investments, Healthpeak Properties, and Agree Realty Corporation.

📈 Agree Realty (ADC) announced an increase in its dividend payout for this week's coverage.

🏥 AGNC Investment Corp. (AGNC) declared a dividend to its shareholders.

🏥 Healthpeak Properties, Inc. (DOC) also declared dividends during this reporting period.

💊 The article mentions upcoming dividend declarations from major players like AbbVie (ABBV) and Abbott Labs (ABT).

📉 The update provides a summary of current market activity for investors focused on income-generating stocks.

🏦 Several ETFs are listed as related entities, including the iShares Select Dividend ETF (DVY) and Vanguard High Dividend Yield Index Fund (VYM).

Bullish Signals
  • AbbVie (ABBV) to declare dividends next week, committing to shareholder returns.
  • Agree Realty (ADC) raised dividends, reflecting strong cash flow and earnings confidence.
  • AGNC Investment Corp. declared dividend payment, maintaining status as attractive income stock.
Risk Factors
  • No negative aspects or risks identified.
  • No declining metrics, regulatory concerns, or threats.
  • Neutral article lacks bearish financial data.
Bullish Signals
  • AbbVie (ABBV) is expected to declare dividends next week, signaling continued commitment to shareholder returns.
  • Agree Realty (ADC) announced an increase in its dividend payouts, reflecting strong cash flow generation and confidence in future earnings.
  • AGNC Investment Corp. (AGNC) declared a new dividend payment, maintaining its status as an attractive income stock for investors seeking reliable yields.
Risk Factors
  • The article contains no negative aspects or risks related to AbbVie (ABBV).
  • There is no mention of declining metrics, regulatory concerns, competitive threats, or downside catalysts for AbbVie.
  • The provided text is a neutral dividend roundup and lacks specific financial data that could be interpreted as bearish.
Bullish +70

AbbVie: Fairly Valued And Positioned For Growth

📈 AbbVie earnings projected to grow 19.1% YoY with EPS of $2.93 in Q1 2026.

💰 Revenue expected to reach $14.72B, marking a 10.3% year-over-year increase for the quarter.

💊 Skyrizi and Rinvoq driving recovery as Humira decline is offset by new products.

⚠ Competition from J&J's Tremfya poses key risk to monitor closely ahead of April 29 earnings.

📈 AbbVie (ABBV) is positioned for a growth recovery in both profits and dividends according to the latest investment analysis.

💰 Upcoming First Quarter 2026 earnings are projected to show EPS of $2.93, representing a 19.1% year-over-year increase.

📊 Revenue for the quarter is expected to reach $14.72 billion, marking a 10.3% growth compared to the previous year.

💵 Dividend growth is stabilizing with the most recent annual increase recorded at 5.48%.

💊 The portfolio's revenue recovery is being driven by Skyrizi and Rinvoq offsetting the decline from Humira.

⚠️ Competitive threats from Johnson & Johnson's Tremfya and Icotyde are noted as key risks to monitor closely.

📅 FQ1 earnings results are expected to be released on April 29, 2026.

🔍 The analysis emphasizes the need to watch for potential deceleration in growth after recent increases.

Bullish Signals
  • FQ1 2026 EPS up 19.1% to $2.93, revenue rising 10.3% to $14.72B.
  • Dividend increased 5.48%, signaling stabilization after deceleration.
  • Skyrizi and Rinvoq offsetting Humira decline for stability.
  • Earnings expected April 29, supporting profit recovery.
  • Stock fairly valued with strong growth trajectory.
Risk Factors
  • Skyrizi/Rinvoq only partially offset Humira's revenue decline, showing patent dependency risk.
  • Johnson & Johnson's Tremfya/Icotyde threaten future market share for AbbVie biologics.
  • Dividend growth decelerates despite increases, indicating potential shareholder return volatility.
  • Analyst holds JNJ shares, creating a conflict of interest in assessing competitor risks.
Bullish Signals
  • Upcoming FQ1 2026 earnings are expected to show robust growth, with EPS of $2.93 representing a 19.1% year-over-year increase and revenue of $14.72B up 10.3%.
  • Dividend growth appears to be recovering with the latest annual increase at 5.48%, signaling potential stabilization after recent deceleration.
  • Skyrizi and Rinvoq are effectively offsetting Humira's decline, providing a solid foundation for continued revenue stability.
  • AbbVie is positioned for a profit recovery with earnings expected on April 29.
  • The stock is described as fairly valued and well-positioned for future growth trajectories.
Risk Factors
  • Skyrizi and Rinvoq are only partially offsetting the significant decline in revenue from Humira, indicating lingering dependency on expiring patents.
  • Competitive threats from Johnson & Johnson's Tremfya and Icotyde warrant close monitoring as they could erode future market share for AbbVie's core biologics portfolio.
  • The article notes recent deceleration in dividend growth despite the latest annual increase, suggesting volatility in shareholder returns.
  • Analyst disclosure reveals a beneficial long position in shares of JNJ, which may create a potential conflict of interest regarding the assessment of competitive threats from Tremfya and Icotyde.